RNA

-- ATR 1072 is the company's first precision cardiology program to enter the clinic -- -- Corventis™ will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease -- SAN DIEGO, July 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application allowing the Company to move forward with its Corventis™ Phase 1/2 clinical trial designed to evaluate ATR 1072 for the treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome. "PRKAG2 syndrome and other rare genetic cardiomyopathies represent a profound unmet need — these are progressive, life-altering and life-threatening diseases that often strike early, affect multiple members of the same family, and have no approved therapy to address their root cause," said Kathleen Gallagher, President and Chief Executive Officer, Atrium Therapeutics.

SAN DIEGO, June 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on June 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of eight non-executive individuals newly hired by the Company. The employees received, in the aggregate, non-qualified stock options to purchase 66,000 shares of the Company's common stock, par value $0.001 per share, with an exercise price of $12.66 per share, the closing price of the Company's common stock as reported by Nasdaq on the last date of trading preceding the effective date of the grant, 25% of which will vest and become exercisable on the first anniversary of the grant date, and the remaining underlying shares will vest in 36 substantially equal installments each month thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 33,000 shares of the Company's common stock, 25% of which will vest in the first anniversary of the grant date, and the remaining underlying shares will vest in three substantially equal installments each year thereafter, subject to the employee's continued service with the Company through each applicable vesting date, or collectively, the "Awards.

SAN DIEGO, May 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate progress following its launch as a public company. "Our focused pipeline, strong cash balance and experienced team are driving significant momentum as we build a dedicated precision cardiology company," said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics.

SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE: BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration.

SAN DIEGO, April 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on April 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of seven non-executive individuals newly hired by the Company. The employees received, in the aggregate, non-qualified stock options to purchase 101,250 shares of the Company's common stock, par value $0.001 per share, with an exercise price of $14.30 per share, the closing price of the Company's common stock as reported by Nasdaq on the effective date of the grant, 25% of which will vest and become exercisable on the first anniversary of the grant date, and the remaining underlying shares will vest in 36 substantially equal installments each month thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 50,625 shares of the Company's common stock, 25% of which will vest in the first anniversary of the grant date, and the remaining underlying shares will vest in three substantially equal installments each year thereafter, subject to the employee's continued service with the Company through each applicable vesting date, or collectively, the "Awards.